Phreesia, Inc. (NYSE:PHR) COO Sells $105,781.14 in Stock

Phreesia, Inc. (NYSE:PHR - Get Free Report) COO Evan Roberts sold 3,519 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $30.06, for a total value of $105,781.14. Following the completion of the sale, the chief operating officer now owns 741,197 shares of the company's stock, valued at $22,280,381.82. This represents a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Evan Roberts also recently made the following trade(s):

• On Thursday, February 13th, Evan Roberts sold 16,005 shares of Phreesia stock. The stock was sold at an average price of $30.00, for a total value of $480,150.00.
• On Monday, January 27th, Evan Roberts sold 10,716 shares of Phreesia stock. The stock was sold at an average price of $27.48, for a total value of $294,475.68.
• On Tuesday, January 21st, Evan Roberts sold 12,749 shares of Phreesia stock. The stock was sold at an average price of $27.31, for a total value of $348,175.19.
• On Wednesday, January 15th, Evan Roberts sold 1,785 shares of Phreesia stock. The stock was sold at an average price of $26.98, for a total value of $48,159.30.
• On Wednesday, January 8th, Evan Roberts sold 2,681 shares of Phreesia stock. The stock was sold at an average price of $27.95, for a total value of $74,933.95.
• On Monday, January 6th, Evan Roberts sold 2,873 shares of Phreesia stock. The stock was sold at an average price of $26.61, for a total value of $76,450.53.

Phreesia Stock Performance

Shares of NYSE:PHR traded down $1.07 during trading on Monday, hitting $27.15. The stock had a trading volume of 399,788 shares, compared to its average volume of 386,314. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $30.53. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of -18.47 and a beta of 0.96. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The stock has a 50-day simple moving average of $27.32 and a two-hundred day simple moving average of $23.90.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings data on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm had revenue of $106.80 million during the quarter, compared to analysts' expectations of $106.33 million. During the same period last year, the business posted ($0.58) earnings per share. The company's revenue for the quarter was up 16.6% compared to the same quarter last year. On average, equities research analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Piper Sandler reissued an "overweight" rating and issued a $33.00 price target (up from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Truist Financial increased their price target on Phreesia from $31.00 to $34.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Citigroup increased their price target on Phreesia from $31.00 to $35.00 and gave the company a "buy" rating in a research note on Friday, January 10th. Royal Bank of Canada upgraded Phreesia from a "sector perform" rating to an "outperform" rating and increased their price target for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Finally, Robert W. Baird decreased their price target on Phreesia from $34.00 to $30.00 and set an "outperform" rating for the company in a research note on Wednesday, December 11th. Thirteen investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Phreesia presently has an average rating of "Buy" and a consensus target price of $31.15.

Institutional Trading of Phreesia

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Invesco Ltd. grew its holdings in Phreesia by 0.9% during the fourth quarter. Invesco Ltd. now owns 40,249 shares of the company's stock worth $1,013,000 after acquiring an additional 357 shares during the period. NewEdge Advisors LLC grew its holdings in Phreesia by 12.1% during the fourth quarter. NewEdge Advisors LLC now owns 4,256 shares of the company's stock worth $107,000 after acquiring an additional 459 shares during the period. Johnson Financial Group Inc. grew its holdings in Phreesia by 381.3% during the fourth quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company's stock worth $28,000 after acquiring an additional 896 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Phreesia by 3.3% during the third quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company's stock worth $637,000 after acquiring an additional 905 shares during the period. Finally, MetLife Investment Management LLC grew its holdings in Phreesia by 3.8% during the third quarter. MetLife Investment Management LLC now owns 30,781 shares of the company's stock worth $701,000 after acquiring an additional 1,120 shares during the period. 92.10% of the stock is owned by institutional investors and hedge funds.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.